ClinicalTrials.gg
Enrolling by invitationNCT06987058ROVER-01Updated Sep 17, 2026

RVU120 Rollover Study

A Phase 2 interventional study of RVU120 and Ruxolitinib in Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) and High-risk Myelodysplastic Syndrome, sponsored by Ryvu Therapeutics SA. Enrolling by invitation at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Ryvu Therapeutics SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Leukemia, Myeloid, Acute with a site in Poland — 14 open to participants now, 23 under way, 11 of them phase 3. Leukemia, Myeloid, Acute · Poland.

Planned enrollment
73rd of 75
14 · median 255
Started
2025
with 4 others
Phase 2
17 of 76
4 open now
Primary completion
2026-12
later than 4 of 22 live
Registered
74th of 76
by date
Lead sponsor
4 of 76
Ryvu Therapeutics SA

Among the 76 studies in Leukemia, Myeloid, Acute with a site in Poland, this one is the 73rd largest by planned enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 4 of the 22 other live ones, and was the 74th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

14 of the 76 studies in Leukemia, Myeloid, Acute with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Leukemia, Myeloid, Acute with a site in Poland, or all of them as a file.
02

Study summary

This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study.

To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.

Read the detailed description

Participants may continue treatment until loss of clinical benefit as judged by the investigator, unacceptable toxicity, start of subsequent anticancer therapy, or until any other criterion for withdrawal from the treatment or the study is met.

03

Conditions studied

  • Advanced Solid Tumors
  • Acute Myeloid Leukaemia (AML)
  • High-risk Myelodysplastic Syndrome

Keywords

  • Relapse
  • Refractory
  • Metastatic
  • Advanced
  • Solid Tumor
  • AML
  • Myelodysplastic syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles.
  2. The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor.
  3. The participant does not have access to commercially available comparator anticancer therapy.
  4. use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  5. The participant signed the rollover study ICF prior to any study-related procedure or study data collection.
  6. The participant agrees not to donate blood during study participation and until 28 weeks (\~6.5 months) after the last dose.
  7. The investigator considers the participant to be eligible for participation in the rollover study.

Exclusion criteria

Exclusion Criteria:

  1. Presence of toxicity that cannot be adequately managed.
  2. Concurrent participation in any therapeutic clinical study other than the parent study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    RVU120 single agent

    Study intervention is assigned in accordance with the parent protocol and consists of RVU120-based treatment.

    Drug: RVU120

  • Experimental
    RVU120 + Ruxolitinib

    Drug: RVU120 · Drug: Ruxolitinib

Interventions

  • DrugRVU120

    Drug pages: SEL-120 · Romaciclib · Silevertinib

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

    Also known as: SEL120

  • Selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (Safety and Tolerability)

    Number and grade of adverse events assessed by CTCAE v5.0

    Time frame: 12 months

Secondary outcomes

  1. Duration of response

    Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study.

    Time frame: 12 months

07

Study locations

7 sites
  • Hôpital l'Archet 1 - CHU de Nice; Service Hématologie Clinique
    Nice, France
  • Hôpital Haut-Lévêque- CHU de Bordeaux, Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire
    Pessac, France
  • M2M Med Sp. Z o.o.
    Chorzów, Poland
  • CWBK UCK Ośrodek Badań Klinicznych Wczesnych Faz
    Gdansk, Poland
  • Pratia Hematologia Sp. z o.o. Pratia Onkologia Katowice
    Katowice, Poland
  • SPZOZ Szpital Uniwersytecki w Krakowie
    Krakow, Poland
  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Terapii Komórkowych i Chorób Wewnętrznych
    Wroclaw, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's planned 12 months is below that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 23, 2025
StartActual
Dec 4, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06987058
Lead sponsor
Ryvu Therapeutics SA
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Dec 4, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SEL-120 · Romaciclib · Silevertinib

Start the discussion